From small to powerful: The fragments universe and its 'chem-appeal'

Current Medicinal Chemistry

Volumn 20, Issue 11, 2013, Pages 1355-1381

  Sancineto, Luca ^a   Massari, Serena ^a   Iraci, Nunzio ^a   Tabarrini, Oriana ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Fbdd; Fragment Library Design; Fragment Optimization; Nmr Screening; Spr Based Screening; X Ray Crystallography

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTIVIRUS AGENT; AT 13387; AT 7519; AURORA A KINASE; AURORA KINASE INHIBITOR; BACTERIAL RNA; CASPASE 3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHLOROBENZENE; CISAPRIDE; CYSTEINE; DARAPLADIB; DORAMAPIMOD; ENDOTHIAPEPSIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROGEN; INTERLEUKIN 1BETA CONVERTING ENZYME; LINIFANIB; MARAVIROC; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NAVITOCLAX; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NVPAUY 922; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RILPIVIRINE; RNA BINDING PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; UK 107543; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ALLOSTERISM; ARTICLE; AWARENESS; BIOSENSOR; CHEMICAL COMPOSITION; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MARKETING; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; FRAGMENT BASED DRUG DESIGN; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHOBICITY; IC 50; MASS SPECTROMETRY; MELANOMA; MOLECULAR DOCKING; MOLECULAR LIBRARY; MOLECULAR WEIGHT; MOLECULE; MONTE CARLO METHOD; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; SPIN LABELING; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; THERMODYNAMICS; WORKFLOW; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; SMALL MOLECULE LIBRARIES; SURFACE PLASMON RESONANCE;

EID: 84877938835     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990111     Document Type: Article

References (178)

1. Martin, Y. C. Challenges and prospects for computational aids to molecular diversity. Perspect. Drug Discov. Des., 1997, 7-8, 159-172.
2. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragmentbased lead discovery. Nat. Rev. Drug Discov., 2004, 3(8), 660-672.
3. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery. Nat. Chem., 2009, 1(3), 187-192.
4. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comp. Sci., 2001, 41(3), 856-864.
5. Schuffenhauer, A.; Ruedisser, S.; Marzinzik, A. L.; Jahnke, W.; Blommers, M.; Selzer, P.; Jacoby, E. Library design for fragment based screening. Curr. Top. Med. Chem. 2005, 5(8), 751-762.
6. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA,1999, 96(18), 9997-10002.
7. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliver. Rev., 2001, 46(1-3), 3-26.
8. Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: leads by design. Drug Discov. Today,2005, 10(14), 987-992.
9. Hajduk, P. J. Fragment-based drug design: How big is too big? J. Med. Chem., 2006,49(24), 6972-6976.
10. Verdonk, M. L.; Giangreco, I.; Hall, R. J.; Korb, O.; Mortenson, P. N.; Murray, C. W. Docking performance of fragments and druglike compounds. J. Med. Chem., 2011, 54(15), 5422-5431.
11. Ward, R. A.; Brassington, C.; Breeze, A. L.; Caputo, A.; Critchlow, S.; Davies, G.; Goodwin, L.; Hassall, G.; Greenwood, R.; Holdgate, G. A.; Mrosek, M.; Norman, R. A.; Pearson, S.; Tart, J.; Tucker, J. A.; Vogtherr, M.; Whittaker, D.; Wingfield, J.; Winter, J.; Hudson, K. Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation. J. Med. Chem., 2012, 55(7), 3285-3306.
12. Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today,2005, 10(7), 464-469.
13. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The Design of Leadlike Combinatorial Libraries. Angew. Chem. Int. Ed. Engl., 1999, 38(24), 3743-3748.
14. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A rule of three for fragment-based lead discovery? Drug Discov. Today,2003, 8(19), 876-877.
15. Mitchell, T.; Showell, G. A. Design strategies for building druglike chemical libraries. Curr. Opin. Drug Discov. Devel., 2001, 4(3), 314-318.
16. Koster, H.; Craan, T.; Brass, S.; Herhaus, C.; Zentgraf, M.; Neumann, L.; Heine, A.; Klebe, G. A Small Nonrule of 3 Compatible Fragment Library Provides High Hit Rate of Endothiapepsin Crystal Structures with Various Fragment Chemotypes. J. Med. Chem., 2011, 54(22), 7784-7796.
17. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci., 1998, 38(3), 511-522.
18. Knehans, T.; Schuller, A.; Doan, D. N.; Nacro, K.; Hill, J.; Guntert, P.; Madhusudhan, M. S.; Weil, T.; Vasudevan, S. G. Structureguided fragment-based in silico drug design of dengue protease inhibitors. J. Comput. Aid. Mol. Des., 2011, 25(3), 263-274.
19. Murchie, A. I.; Davis, B.; Isel, C.; Afshar, M.; Drysdale, M. J.; Bower, J.; Potter, A. J.; Starkey, I. D.; Swarbrick, T. M.; Mirza, S.; Prescott, C. D.; Vaglio, P.; Aboul-ela, F.; Karn, J. Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol., 2004, 336(3), 625-638.
20. Morley, S. D.; Afshar, M. Validation of an empirical RNA-ligand scoring function for fast flexible docking using Ribodock. J. Comput. Aided Mol. Des., 2004, 18(3), 189-208.
21. Lind, K. E.; Du, Z.; Fujinaga, K.; Peterlin, B. M.; James, T. L. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem. Biol., 2002, 9(2), 185-193.
22. Detering, C.; Varani, G. Validation of automated docking programs for docking and database screening against RNA drug targets. J. Med. Chem., 2004, 47(17), 4188-4201.
23. Guilbert, C.; James, T. L. Docking to RNA via root-mean-squaredeviation- driven energy minimization with flexible ligands and flexible targets. J. Chem. Inf. Model., 2008, 48(6), 1257-1268.
24. Bodoor, K.; Boyapati, V.; Gopu, V.; Boisdore, M.; Allam, K.; Miller, J.; Treleaven, W. D.; Weldeghiorghis, T.; Aboul-ela, F. Design and implementation of an ribonucleic acid (RNA) directed fragment library. J. Med. Chem., 2009, 52(12), 3753-3761.
25. Schuffenhauer, A.; Ertl, P.; Roggo, S.; Wetzel, S.; Koch, M. A.; Waldmann, H. The scaffold tree-Visualization of the scaffold universe by hierarchical scaffold classification. J. Chem. Inf. Model., 2007, 47(1), 47-58.
26. Griffey, R. H.; Sannes-Lowery, K. A.; Drader, J. J.; Mohan, V.; Swayze, E. E.; Hofstadler, S. A. Characterization of low-affinity complexes between RNA and small molecules using electrospray ionization mass spectrometry. J. Am. Chem. Soc., 2000, 122(41), 9933-9938.
27. Yu, L. P.; Oost, T. K.; Schkeryantz, J. M.; Yang, J. G.; Janowick, D.; Fesik, S. W. Discovery of aminoglycoside mimetics by NMRbased screening of Escherichia coli A-site RNA. J. Am. Chem. Soc., 2003, 125(15), 4444-4450.
28. Siegal, G.; Ab, E.; Schultz, J. Integration of fragment screening and library design. Drug Discov. Today,2007, 12(23-24), 1032-1039.
29. Boettcher, A.; Ruedisser, S.; Erbel, P.; Vinzenz, D.; Schiering, N.; Hassiepen, U.; Rigollier, P.; Mayr, L. M.; Woelcke, J. Fragmentbased screening by biochemical assays: Systematic feasibility studies with trypsin and MMP12. J. Biomol. Screen., 2010, 15(9), 1029-1041.
30. Dalvit, C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov. Today,2009,14(21-22), 1051-1057.
31. Maple, H. J.; Garlish, R. A.; Rigau-Roca, L.; Porter, J.; Whitcombe, I.; Prosser, C. E.; Kennedy, J.; Henry, A. J.; Taylor, R. J.; Crump, M. P.; Crosby, J. Automated protein-ligand interaction screening by mass spectrometry. J. Med. Chem., 2012, 55(2), 837-851.
32. Drinkwater, N.; Vu, H.; Lovell, K. M.; Criscione, K. R.; Collins, B. M.; Prisinzano, T. E.; Poulsen, S. A.; McLeish, M. J.; Grunewald, G. L.; Martin, J. L. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors. Biochem. J., 2010, 431(1), 51-61.
33. Morcos, E. F.; Kussrow, A.; Enders, C.; Bornhop, D. Free-solution interaction assay of carbonic anhydrase to its inhibitors using backscattering interferometry. Electrophoresis,2010, 31(22), 3691-6395.
34. Fruh, V.; Zhou, Y.; Chen, D.; Loch, C.; Ab, E.; Grinkova, Y. N.; Verheij, H.; Sligar, S. G.; Bushweller, J. H.; Siegal, G. Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB. Chem. Biol., 2010, 17(8), 881-891.
35. Calleri, E.; Fracchiolla, G.; Montanari, R.; Pochetti, G.; Lavecchia, A.; Loiodice, F.; Laghezza, A.; Piemontese, L.; Massolini, G.; Temporini, C. Frontal affinity chromatography with MS detection of the ligand binding domain of PPARgamma receptor: ligand affinity screening and stereoselective ligand-macromolecule interaction. J. Chromatogr. A., 2012, 1232, 84-92.
36. Navratilova, I.; Hopkins, A. L. Emerging role of surface plasmon resonance in fragment-based drug discovery. Future Med. Chem., 2011, 3(14), 1809-1820.
37. Fitzpatrick, P. A.; Steinmetz, A. C.; Ringe, D.; Klibanov, A. M. Enzyme crystal structure in a neat organic solvent. Proc. Natl. Acad. Sci. USA,1993, 90(18), 8653-8657.
38. Mattos, C.; Ringe, D. Locating and characterizing binding sites on proteins. Nat. Biotechnol., 1996, 14(5), 595-9.
39. English, A. C.; Done, S. H.; Caves, L. S.; Groom, C. R.; Hubbard, R. E. Locating interaction sites on proteins: the crystal structure of thermolysin soaked in 2% to 100% isopropanol. Proteins,1999, 37(4), 628-640.
40. English, A. C.; Groom, C. R.; Hubbard, R. E. Experimental and computational mapping of the binding surface of a crystalline protein. Protein Eng., 2001, 14(1), 47-59.
41. Davies, T. G.; Tickle, I. J. Fragment screening using X-ray crystallography. Top. Curr. Chem., 2012, 317, 33-59.
42. Jhoti, H.; Cleasby, A.; Verdonk, M.; Williams, G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr. Opin. Chem. Biol., 2007, 11(5), 485-493.
43. Salon, J. A.; Lodowski, D. T.; Palczewski, K. The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol. Rev., 2011, 63(4), 901-937.
44. Wasserman, S. R.; Koss, J. W.; Sojitra, S. T.; Morisco, L. L.; Burley, S. K. Rapid-access, high-throughput synchrotron crystallography for drug discovery. Trends Pharmacol. Sci., 2012, 33(5), 261-267.
45. Davies, T. G.; Woodhead, S. J.; Collins, I. Fragment-based discovery of inhibitors of protein kinase B. Curr. Top. Med. Chem., 2009, 9(18), 1705-1717.
46. Davies, T. G.; Verdonk, M. L.; Graham, B.; Saalau-Bethell, S.; Hamlett, C. C.; McHardy, T.; Collins, I.; Garrett, M. D.; Workman, P.; Woodhead, S. J.; Jhoti, H.; Barford, D. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. Mol. Biol., 2007, 367(3), 882-894.
47. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of inhibitors of protein kinase B using fragment-based lead discovery. J. Med. Chem., 2007, 50(10), 2293-2296.
48. Wyatt, P. G.; Woodhead, A. J.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Davis, D. J.; Devine, L. A.; Early, T. R.; Feltell, R. E.; Lewis, E. J.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Reule, M.; Saxty, G.; Seavers, L. C.; Smith, D. M.; Squires, M. S.; Trewartha, G.; Walker, M. T.; Woolford, A. J. Identification of N-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based Xray crystallography and structure based drug design. J. Med. Chem., 2008, 51(16), 4986-4999.
49. Howard, S.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Curry, J.; Devine, L. A.; Early, T. R.; Fazal, L.; Gill, A. L.; Heathcote, M.; Maman, S.; Matthews, J. E.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Rees, D. C.; Reule, M.; Tisi, D.; Williams, G.; Vinkovic, M.; Wyatt, P. G. Fragmentbased discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem., 2009, 52(2), 379-388.
50. Bauman, J. D.; Patel, D.; Arnold, E. Fragment screening and HIV therapeutics. Top. Curr. Chem., 2012, 317, 181-200.
51. Saalau-Bethell, S. M.; Woodhead, A. J.; Chessari, G.; Carr, M. G.; Coyle, J.; Graham, B.; Hiscock, S. D.; Murray, C. W.; Pathuri, P.; Rich, S. J.; Richardson, C. J.; Williams, P. A.; Jhoti, H. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat. Chem. Biol., 2012, 8(11), 920-925.
52. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science,1996, 274(5292), 1531-1534.
53. Fernandez, C.; Jahnke, W. New Approaches for NMR Screening in Drug Discovery. Drug Discov. Today: Techn., 2004, 1(3), 277-283.
54. Jahnke, W. Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility. J. Biomol. NMR,2007, 39(2), 87-90.
55. Pellecchia, M.; Bertini, I.; Cowburn, D.; Dalvit, C.; Giralt, E.; Jahnke, W.; James, T. L.; Homans, S. W.; Kessler, H.; Luchinat, C.; Meyer, B.; Oschkinat, H.; Peng, J.; Schwalbe, H.; Siegal, G. Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug Discov., 2008, 7(9), 738-745.
56. Vanwetswinkel, S.; Heetebrij, R. J.; van Duynhoven, J.; Hollander, J. G.; Filippov, D. V.; Hajduk, P. J.; Siegal, G. TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem. Biol., 2005, 12(2), 207-216.
57. Johnson, E. C.; Feher, V. A.; Peng, J. W.; Moore, J. M.; Williamson, J. R. Application of NMR SHAPES screening to an RNA target. J. Am. Chem. Soc., 2003, 125(51), 15724-15725.
58. Davidson, A.; Begley, D. W.; Lau, C.; Varani, G. A smallmolecule probe induces a conformation in HIV TAR RNA capable of binding drug-like fragments. J. Mol. Biol., 2011, 410(5), 984-996.
59. Parsons, J.; Castaldi, M. P.; Dutta, S.; Dibrov, S. M.; Wyles, D. L.; Hermann, T. Conformational inhibition of the hepatitis C virus internal ribosome entry site RNA. Nat. Chem. Biol., 2009, 5(11), 823-825.
60. Seth, P. P.; Miyaji, A.; Jefferson, E. A.; Sannes-Lowery, K. A.; Osgood, S. A.; Propp, S. S.; Ranken, R.; Massire, C.; Sampath, R.; Ecker, D. J.; Swayze, E. E.; Griffey, R. H. SAR by MS: discovery of a new class of RNA-binding small molecules for the hepatitis C virus: internal ribosome entry site IIA subdomain. J. Med. Chem., 2005, 48(23), 7099-7102.
61. Gatto, B.; Tabarrini, O.; Massari, S.; Giaretta, G.; Sabatini, S.; Del Vecchio, C.; Parolin, C.; Fravolini, A.; Palumbo, M.; Cecchetti, V. 2-Phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction. ChemMedChem,2009, 4(6), 935-938.
62. Tabarrini, O.; Massari, S.; Cecchetti, V. 6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. Future Med. Chem., 2010, 2(7), 1161-1180.
63. Tabarrini, O.; Massari, S.; Sancineto, L.; Daelemans, D.; Sabatini, S.; Manfroni, G.; Cecchetti, V.; Pannecouque, C. Structural investigation of the naphthyridone scaffold: identification of a 1,6-naphthyridone derivative with potent and selective anti-HIV activity. ChemMedChem,2011, 6 (7), 1249-1257.
64. De Crescenzo, G.; Boucher, C.; Durocher, Y.; Jolicoeur, M. Kinetic Characterization by Surface Plasmon Resonance-Based Biosensors: Principles and Emerging Trands. Cell Mol. Bioeng., 2008, 1(4), 204-215.
65. Navratilova, I.; Papalia, G. A.; Rich, R. L.; Bedinger, D.; Brophy, S.; Condon, B.; Deng, T.; Emerick, A. W.; Guan, H. W.; Hayden, T.; Heutmekers, T.; Hoorelbeke, B.; McCroskey, M. C.; Murphy, M. M.; Nakagawa, T.; Parmeggiani, F.; Qin, X.; Rebe, S.; Tomasevic, N.; Tsang, T.; Waddell, M. B.; Zhang, F. F.; Leavitt, S.; Myszka, D. G. Thermodynamic benchmark study using Biacore technology. Anal. Biochem., 2007, 364(1), 67-77.
66. Cullen, D. C.; Brown, R. G.; Lowe, C. R. Detection of immunocomplex formation via surface plasmon resonance on gold-coated diffraction gratings. Biosensors,1987, 3(4), 211-225.
67. Markgren, P. O.; Hamalainen, M.; Danielson, U. H. Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology. Anal. Biochem., 2000, 279(1), 71-78.
68. Kampranis, S. C.; Gormley, N. A.; Tranter, R.; Orphanides, G.; Maxwell, A. Probing the binding of coumarins and cyclothialidines to DNA gyrase. Biochemistry-Us,1999, 38(7), 1967-1976.
69. Strandh, M.; Persson, B.; Roos, H.; Ohlson, S. Studies of interactions with weak affinities and low-molecular-weight compounds using surface plasmon resonance technology. J. Mol. Recognit., 1998, 11(1-6), 188-90.
70. Markgren, P. O.; Hamalainen, M.; Danielson, U. H. Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology. Anal. Biochem., 1998, 265(2), 340-350.
71. Huber, W. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. J. Mol. Recognit., 2005, 18(4), 273-281.
72. Geitmann, M.; Elinder, M.; Seeger, C.; Brandt, P.; de Esch, I. J.; Danielson, U. H. Identification of a Novel Scaffold for Allosteric Inhibition of Wild Type and Drug Resistant HIV-1 Reverse Transcriptase by Fragment Library Screening. J. Med. Chem., 2011, 54(3), 699-708.
73. Elinder, M.; Geitmann, M.; Gossas, T.; Kallblad, P.; Winquist, J.; Nordstrom, H.; Hamalainen, M.; Danielson, U. H. Experimental validation of a fragment library for lead discovery using SPR biosensor technology. J. Biomol. Screen., 2011, 16(1), 15-25.
74. Perspicace, S.; Banner, D.; Benz, J.; Muller, F.; Schlatter, D.; Huber, W. Fragment-based screening using surface plasmon resonance technology. J. Biomol. Screen., 2009, 14(4), 337-349.
75. Kuglstatter, A.; Stahl, M.; Peters, J. U.; Huber, W.; Stihle, M.; Schlatter, D.; Benz, J.; Ruf, A.; Roth, D.; Enderle, T.; Hennig, M. Tyramine fragment binding to BACE-1. Bioorg. Med. Chem. Lett., 2008, 18(4), 1304-1307.
76. Rich, R. L.; Quinn, J. G.; Morton, T.; Stepp, J. D.; Myszka, D. G. Biosensor-based fragment screening using FastStep injections. Anal. Biochem., 2010, 407(2), 270-277.
77. Nordstrom, H.; Gossas, T.; Hamalainen, M.; Kallblad, P.; Nystrom, S.; Wallberg, H.; Danielson, U. H. Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J. Med. Chem., 2008, 51(12), 3449-3459.
78. Congreve, M.; Rich, R. L.; Myszka, D. G.; Figaroa, F.; Siegal, G.; Marshall, F. H. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. Meth. Enzymol., 2011, 493, 115-136.
79. Navratilova, I.; Besnard, J.; Hopkins, A. L. Screening for GPCR Ligands Using Surface Plasmon Resonance. ACS Med. Chem. Lett., 2011, 2(7), 549-554.
80. Orita, M.; Ohno, K.; Niimi, T. Two 'Golden Ratio' indices in fragment-based drug discovery. Drug Discov. Today,2009, 14(5-6), 321-328.
81. Hofstadler, S. A.; Sannes-Lowery, K. A.; Crooke, S. T.; Ecker, D. J.; Sasmor, H.; Manalili, S.; Griffey, R. H. Multiplexed screening of neutral mass-tagged RNA targets against ligand libraries with electrospray ionization FTICR MS: A paradigm for highthroughout affinity screening. Anal. Chem., 1999, 71(16), 3436-3440.
82. Sannes-Lowery, K. A.; Drader, J.; Griffey, R. H.; Hofstadler, S. A. High-Performance Mass Spectrometry as a Drug Discovery Tool: a High-Throughput Screening Assay to Identify RNA-Binding Ligands. Proc. SPIE-Int. Soc. Opt. Eng., 2001, 4264, 27-36.
83. Sannes-Lowery, K. A.; Griffey, R. H.; Hofstadler, S. A. Measuring dissociation constants of RNA and aminoglycoside antibiotics by electrospray ionization mass spectrometry. Anal. Biochem., 2000, 280(2), 264-71.
84. Liu, L.; Bagal, D.; Kitova, E. N.; Schnier, P. D.; Klassen, J. S. Hydrophobic protein-ligand interactions preserved in the gas phase. J. Am. Chem. Soc., 2009, 131(44), 15980-15981.
85. Hannah, V. V.; Atmanene, C.; Zeyer, D.; Van Dorsselaer, A.; Sanglier-Cianferani, S. Native MS: an 'ESI' way to support structure-and fragment-based drug discovery. Future Med. Chem., 2010, 2(1), 35-50.
86. Kasai, K.; Ishii, S. Affinity chromatography of trypsin and related enzymes. I. Preparation and characteristics of an affinity adsorbent containing tryptic peptides from protamine as ligands. J. Biochem., 1975, 78(4), 653-662.
87. Schriemer, D. C.; Bundle, D. R.; Li, L.; Hindsgaul, O. Micro-scale frontal affinity chromatography with mass spectrometric detection: A new method for the screening of compound libraries. Angew. Chem. Int. Ed., 1998, 37(24), 3383-3387.
88. Slon-Usakiewicz, J. J.; Ng, W.; Dai, J. R.; Pasternak, A.; Redden, P. R. Frontal affinity chromatography with MS detection (FACMS) in drug discovery. Drug Discov. Today,2005, 10(6), 409-416.
89. Chan, N.; Lewis, D.; Kelly, M.; Ng, E. S. M.; Schriemer, D. C., In Mass Spectrometry in Medicinal Chemistry, Wanner, K. T.; Hafner, G., Eds. Wiley-VCH Weinheim, 2007.
90. Kasai, K.; Oda, Y.; Nishikata, M.; Ishii, S. Frontal affinity chromatography: theory for its application to studies on specific interactions of biomolecules. J. Chromatogr., 1986, 376, 33-47.
91. Toledo-Sherman, L.; Deretey, E.; Slon-Usakiewicz, J. J.; Ng, W.; Dai, J. R.; Foster, J. E.; Redden, P. R.; Uger, M. D.; Liao, L. C.; Pasternak, A.; Reid, N. Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. J. Med. Chem., 2005, 48(9), 3221-3230.
92. Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; Wells, J. A. Site-directed ligand discovery. Proc. Natl. Acad. Sci. USA,2000, 97(17), 9367-9372.
93. Erlanson, D. A.; Hansen, S. K. Making drugs on proteins: sitedirected ligand discovery for fragment-based lead assembly. Curr. Opin. Chem. Biol., 2004, 8(4), 399-406.
94. Erlanson, D. A.; Lam, J. W.; Wiesmann, C.; Luong, T. N.; Simmons, R. L.; DeLano, W. L.; Choong, I. C.; Burdett, M. T.; Flanagan, W. M.; Lee, D.; Gordon, E. M.; O'Brien, T. In situ assembly of enzyme inhibitors using extended tethering. Nat. Biotechnol., 2003, 21(3), 308-314.
95. Choong, I. C.; Lew, W.; Lee, D.; Pham, P.; Burdett, M. T.; Lam, J. W.; Wiesmann, C.; Luong, T. N.; Fahr, B.; DeLano, W. L.; McDowell, R. S.; Allen, D. A.; Erlanson, D. A.; Gordon, E. M.; O'Brien, T. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J. Med. Chem., 2002, 45(23), 5005-5022.
96. Fahr, B. T.; O'Brien, T.; Pham, P.; Waal, N. D.; Baskaran, S.; Raimundo, B. C.; Lam, J. W.; Sopko, M. M.; Purkey, H. E.; Romanowski, M. J. Tethering identifies fragment that yields potent inhibitors of human caspase-1. Bioorg. Med. Chem. Lett., 2006, 16(3), 559-562.
97. Cancilla, M. T.; He, M. M.; Viswanathan, N.; Simmons, R. L.; Taylor, M.; Fung, A. D.; Cao, K.; Erlanson, D. A. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. Bioorg. Med. Chem. Lett., 2008, 18(14), 3978-3981.
98. Erlanson, D. A.; Arndt, J. W.; Cancilla, M. T.; Cao, K.; Elling, R. A.; English, N.; Friedman, J.; Hansen, S. K.; Hession, C.; Joseph, I.; Kumaravel, G.; Lee, W. C.; Lind, K. E.; McDowell, R. S.; Miatkowski, K.; Nguyen, C.; Nguyen, T. B.; Park, S.; Pathan, N.; Penny, D. M.; Romanowski, M. J.; Scott, D.; Silvian, L.; Simmons, R. L.; Tangonan, B. T.; Yang, W.; Sun, L. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg. Med. Chem. Lett., 2011, 21(10), 3078-3083.
99. Macarron, R. Critical review of the role of HTS in drug discovery. Drug Discov. Today,2006, 11(7-8), 277-279.
100. Hughes, S. J.; Millan, D. S.; Kilty, I. C.; Lewthwaite, R. A.; Mathias, J. P.; O'Reilly, M. A.; Pannifer, A.; Phelan, A.; Stuhmeier, F.; Baldock, D. A.; Brown, D. G. Fragment based discovery of a novel and selective PI3 kinase inhibitor. Bioorg. Med. Chem. Lett., 2011, 21(21), 6586-6590.
101. Kobayashi, M.; Retra, K.; Figaroa, F.; Hollander, J. G.; Ab, E.; Heetebrij, R. J.; Irth, H.; Siegal, G. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification. J. Biomol. Screen., 2010, 15(8), 978-989.
102. Durrant, J. D.; Friedman, A. J.; McCammon, J. A. CrystalDock: a novel approach to fragment-based drug design. J. Chem. Inf. Model., 2011, 51(10), 2573-2580.
103. Durrant, J. D.; Hall, L.; Swift, R. V.; Landon, M.; Schnaufer, A.; Amaro, R. E. Novel naphthalene-based inhibitors of Trypanosoma brucei RNA editing ligase 1. PLoS Negl. Trop. Dis., 2010, 4(8), e803.
104. Deng, Y.; Roux, B. Computations of standard binding free energies with molecular dynamics simulations. J. Phys. Chem. B,2009, 113(8), 2234-2246.
105. Clark, M.; Guarnieri, F.; Shkurko, I.; Wiseman, J. Grand canonical Monte Carlo simulation of ligand-protein binding. J. Chem. Inf. Model., 2006, 46(1), 231-242.
106. Clark, M.; Meshkat, S.; Talbot, G. T.; Carnevali, P.; Wiseman, J. S. Fragment-based computation of binding free energies by systematic sampling. J. Chem. Inf. Model., 2009, 49(8), 1901-1913.
107. Moffett, K.; Konteatis, Z.; Nguyen, D.; Shetty, R.; Ludington, J.; Fujimoto, T.; Lee, K. J.; Chai, X.; Namboodiri, H.; Karpusas, M.; Dorsey, B.; Guarnieri, F.; Bukhtiyarova, M.; Springman, E.; Michelotti, E. Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). Bioorg. Med. Chem. Lett., 2011, 21(23), 7155-7165.
108. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol., 2002, 9(4), 268-272.
109. Favia, A. D.; Bottegoni, G.; Nobeli, I.; Bisignano, P.; Cavalli, A. SERAPhiC: a benchmark for in silico fragment-based drug design. J. Chem. Inf. Model., 2011, 51(11), 2882-2896.
110. Hao, G. F.; Wang, F.; Li, H.; Zhu, X. L.; Yang, W. C.; Huang, L. S.; Wu, J. W.; Berry, E. A.; Yang, G. F. Computational Discovery of Picomolar Q(o) Site Inhibitors of Cytochrome bc(1) Complex. J. Am. Chem. Soc., 2012, 134(27), 11168-11176.
111. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins,2006, 65(3), 712-725.
112. Pan, Y.; Gao, D.; Zhan, C. G. Modeling the catalysis of anticocaine catalytic antibody: competing reaction pathways and free energy barriers. J. Am. Chem. Soc., 2008, 130(15), 5140-519.
113. Speck-Planche, A.; Kleandrova, V. V.; Luan, F.; Cordeiro, M. N. Fragment-based QSAR model toward the selection of versatile anti-sarcoma leads. Eur. J. Med. Chem., 2011, 46(12), 5910-6.
114. Speck-Planche, A.; Luan, F.; Cordeiro, M. N. Role of ligand-based drug design methodologies toward the discovery of new anti-Alzheimer agents: futures perspectives in Fragment-Based Ligand Design. Curr Med Chem., 2012, 19(11), 1635-45.
115. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature,2010, 467(7315), 596-599.
116. Mao, W.; Ning, M.; Liu, Z.; Zhu, Q.; Leng, Y.; Zhang, A. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators. Bioorg. Med. Chem., 2012, 20(9), 2982-2991.
117. Edink, E.; Rucktooa, P.; Retra, K.; Akdemir, A.; Nahar, T.; Zuiderveld, O.; van Elk, R.; Janssen, E.; van Nierop, P.; van Muijlwijk-Koezen, J.; Smit, A. B.; Sixma, T. K.; Leurs, R.; de Esch, I. J. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. J. Am. Chem. Soc., 2011, 133(14), 5363-5371.
118. Gibbs, A. C.; Abad, M. C.; Zhang, X.; Tounge, B. A.; Lewandowski, F. A.; Struble, G. T.; Sun, W.; Sui, Z.; Kuo, L. C. Electron density guided fragment-based lead discovery of ketohexokinase inhibitors. J. Med. Chem., 2010, 53(22), 7979-7991.
119. Madden, J.; Dod, J. R.; Godemann, R.; Kraemer, J.; Smith, M.; Biniszkiewicz, M.; Hallett, D. J.; Barker, J.; Dyekjaer, J. D.; Hesterkamp, T. Fragment-based discovery and optimization of BACE1 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(17), 5329-5333.
120. Pomel, V.; Klicic, J.; Covini, D.; Church, D. D.; Shaw, J. P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; Camps, M.; Chabert, C.; Gillieron, C.; Francon, B.; Perrin, D.; Leroy, D.; Gretener, D.; Nichols, A.; Vitte, P. A.; Carboni, S.; Rommel, C.; Schwarz, M. K.; Ruckle, T. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem., 2006, 49(13), 3857-3871.
121. Sledz, P.; Silvestre, H. L.; Hung, A. W.; Ciulli, A.; Blundell, T. L.; Abell, C. Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. J. Am. Chem. Soc., 2010, 132(13), 4544-4545.
122. Jencks, W. P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. USA, 1981, 78(7), 4046-4050.
123. Borsi, V.; Calderone, V.; Fragai, M.; Luchinat, C.; Sarti, N. Entropic contribution to the linking coefficient in fragment based drug design: a case study. J. Med. Chem., 2010, 53(10), 4285-4289.
124. Ichihara, O.; Barker, J.; Law, R. J.; Whittaker, M. Compound Design by Fragment-Linking. Mol. Inform., 2011, 30(4), 298-306.
125. Barker, J. J.; Barker, O.; Courtney, S. M.; Gardiner, M.; Hesterkamp, T.; Ichihara, O.; Mather, O.; Montalbetti, C. A.; Muller, A.; Varasi, M.; Whittaker, M.; Yarnold, C. J. Discovery of a novel Hsp90 inhibitor by fragment linking. ChemMedChem,2010, 5(10), 1697-1700.
126. Cheeseman, J. D.; Corbett, A. D.; Gleason, J. L.; Kazlauskas, R. J. Receptor-assisted combinatorial chemistry: thermodynamics and kinetics in drug discovery. Chemistry,2005, 11(6), 1708-1716.
127. Storm, O.; Luning, U. How to synthesize macrocycles efficiently by using virtual combinatorial libraries. Chemistry,2002, 8 (4), 793-798.
128. Bunyapaiboonsri, T.; Ramstrom, O.; Lohmann, S.; Lehn, J. M.; Peng, L.; Goeldner, M. Dynamic deconvolution of a preequilibrated dynamic combinatorial library of acetylcholinesterase inhibitors. ChemBioChem, 2001, 2(6), 438-444.
129. Maly, D. J.; Choong, I. C.; Ellman, J. A. Combinatorial targetguided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. USA, 2000, 97(6), 2419-2424.
130. Nicolaou, K. C.; Hughes, R.; Cho, S. Y.; Winssinger, N.; Smethurst, C.; Labischinski, H.; Endermann, R. Target-accelerated combinatorial synthesis and discovery of highly potent antibiotics effective against vancomycin-resistant bacteria. Angew. Chem. Int. Ed. Engl., 2000, 39(21), 3823-3828.
131. Rowan, S. J.; Sanders, J. K. M. Macrocycles derived from cinchona alkaloids: A thermodynamic vs kinetic study. J. Org. Chem., 1998, 63(5), 1536-1546.
132. Basso, A.; De Martin, L.; Ebert, C.; Gardossi, L.; Linda, P. High isolated yields in thermodynamically controlled peptide synthesis in toluene catalysed by thermolysin adsorbed on Celite R-640. Chem. Commun., 2000, 6, 467-468.
133. Seeman, J. I., Huisgen, R. in Profiles, pathways and dreams: autobiographies of eminent chemists. Royal Society of Chemistry: Cambridge, 1990.
134. Mamidyala, S. K.; Finn, M. G. In situ click chemistry: probing the binding landscapes of biological molecules. Chem. Soc. Rev., 2010, 39(4), 1252-1261.
135. Lewis, W. G.; Green, L. G.; Grynszpan, F.; Radic, Z.; Carlier, P. R.; Taylor, P.; Finn, M. G.; Sharpless, K. B. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem. Int. Ed. Engl., 2002, 41(6), 1053-1057.
136. Bourne, Y.; Kolb, H. C.; Radic, Z.; Sharpless, K. B.; Taylor, P.; Marchot, P. Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation. Proc. Natl. Acad. Sci. USA,2004, 101(6), 1449-1454.
137. Mocharla, V. P.; Colasson, B.; Lee, L. V.; Roper, S.; Sharpless, K. B.; Wong, C. H.; Kolb, H. C. In situ click chemistry: enzymegenerated inhibitors of carbonic anhydrase II. Angew. Chem. Int. Ed. Engl., 2004, 44(1), 116-120.
138. Whiting, M.; Muldoon, J.; Lin, Y. C.; Silverman, S. M.; Lindstrom, W.; Olson, A. J.; Kolb, H. C.; Finn, M. G.; Sharpless, K. B.; Elder, J. H.; Fokin, V. V. Inhibitors of HIV-1 protease by using in situ click chemistry. Angew. Chem. Int. Ed. Engl., 2006, 45(9), 1435-1439.
139. Hirose, T.; Sunazuka, T.; Sugawara, A.; Endo, A.; Iguchi, K.; Yamamoto, T.; Ui, H.; Shiomi, K.; Watanabe, T.; Sharpless, K. B.; Omura, S. Chitinase inhibitors: extraction of the active framework from natural argifin and use of in situ click chemistry. J. Antibiot. (Tokyo),2009, 62(5), 277-282.
140. Hu, X.; Manetsch, R. Kinetic target-guided synthesis. Chem. Soc. Rev., 2010, 39(4), 1316-1324.
141. Rijkers, D. T.; Merkx, R.; Yim, C. B.; Brouwer, A. J.; Liskamp, R. M. 'Sulfo-click' for ligation as well as for site-specific conjugation with peptides, fluorophores, and metal chelators. J. Pept. Sci., 2010, 16(1), 1-5.
142. Hu, X.; Sun, J.; Wang, H. G.; Manetsch, R. Bcl-XL-templated assembly of its own protein-protein interaction modulator from fragments decorated with thio acids and sulfonyl azides. J. Am. Chem. Soc., 2008, 130(42), 13820-13821.
143. Kulkarni, S. S.; Hu, X.; Doi, K.; Wang, H. G.; Manetsch, R. Screening of protein-protein interaction modulators via sulfo-click kinetic target-guided synthesis. ACS Chem. Biol., 2011, 6(7), 724-732.
144. Grimster, N. P.; Stump, B.; Fotsing, J. R.; Weide, T.; Talley, T. T.; Yamauchi, J. G.; Nemecz, A.; Kim, C.; Ho, K. Y.; Sharpless, K. B.; Taylor, P.; Fokin, V. V. Generation of candidate ligands for nicotinic acetylcholine receptors via in situ click chemistry with a soluble acetylcholine binding protein template. J. Am. Chem. Soc., 2012, 134(15), 6732-6740.
145. Yamauchi, J. G.; Gomez, K.; Grimster, N.; Dufouil, M.; Nemecz, A.; Fotsing, J. R.; Ho, K. Y.; Talley, T. T.; Sharpless, K. B.; Fokin, V. V.; Taylor, P. Synthesizing Selective Agonists for the alpha7 Nicotinic Receptor with in situ Click-Chemistry on Acetylcholine Binding Protein Templates. Mol. Pharmacol., 2012, 82(4), 687-699.
146. Taylor, S. J.; Abeywardane, A.; Liang, S.; Muegge, I.; Padyana, A. K.; Xiong, Z.; Hill-Drzewi, M.; Farmer, B.; Li, X.; Collins, B.; Li, J. X.; Heim-Riether, A.; Proudfoot, J.; Zhang, Q.; Goldberg, D.; Zuvela-Jelaska, L.; Zaher, H.; Li, J.; Farrow, N. A. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J. Med. Chem., 2011, 54(23), 8174-8187.
147. Devel, L.; Czarny, B.; Beau, F.; Georgiadis, D.; Stura, E.; Dive, V. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity. Biochimie,2010, 92(11), 1501-1508.
148. Gao, D. A.; Xiong, Z.; Heim-Riether, A.; Amodeo, L.; August, E. M.; Cao, X.; Ciccarelli, L.; Collins, B. K.; Harrington, K.; Haverty, K.; Hill-Drzewi, M.; Li, X.; Liang, S.; Margarit, S. M.; Moss, N.; Nagaraja, N.; Proudfoot, J.; Roman, R.; Schlyer, S.; Keenan, L. S.; Taylor, S.; Wellenzohn, B.; Wiedenmayer, D.; Li, J.; Farrow, N. A. SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability. Bioorg. Med. Chem. Lett., 2010, 20(17), 5039-5043.
149. Cho, Y. S.; Angove, H.; Brain, C.; Chen, C. H. T.; Cheng, H.; Cheng, R.; Chopra, R.; Chung, K.; Congreve, M.; Dagostin, C.; Davis, D. J.; Felten, R.; Giraldes, J.; Hiscock, S. D.; Kim, S.; Kovats, S.; Lagu, B.; Lewry, K.; Loo, A.; Lu, Y. P.; Luzzio, M.; Maniara, W.; McMenamin, R.; Mortenson, P. N.; Benning, R.; O'Reilly, M.; Rees, D. C.; Shen, J. Q.; Smith, T.; Wang, Y. P.; Williams, G.; Woolford, A. J. A.; Wrona, W.; Xu, M.; Yang, F.; Howard, S. Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. ACS Med. Chem.Lett., 2012, 3(6), 445-449.
150. Artis, D. R.; Lin, J. J.; Zhang, C.; Wang, W.; Mehra, U.; Perreault, M.; Erbe, D.; Krupka, H. I.; England, B. P.; Arnold, J.; Plotnikov, A. N.; Marimuthu, A.; Nguyen, H.; Will, S.; Signaevsky, M.; Kral, J.; Cantwell, J.; Settachatgull, C.; Yan, D. S.; Fong, D.; Oh, A.; Shi, S.; Womack, P.; Powell, B.; Habets, G.; West, B. L.; Zhang, K. Y.; Milburn, M. V.; Vlasuk, G. P.; Hirth, K. P.; Nolop, K.; Bollag, G.; Ibrahim, P. N.; Tobin, J. F. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc. Natl. Acad. Sci. USA,2009, 106(1), 262-267.
151. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S.; Fong, D.; Zhu, Y. L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S. H.; Schlessinger, J.; Zhang, K. Y.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA,2008, 105(8), 3041-3046.
152. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed., 1999, 38(12), 1784-1788.
153. Rauber, C.; Berger, S. Saturation Transfer Difference NMR Studies of the Interaction of the Proteinkinase CK2 with Peptides. Protein Pept. Lett., 2012, 19(9), 934-939
154. Mohebbi, S.; Falcon-Perez, J. M.; Gonzalez, E.; Millet, O.; Mato, J. M.; Kobarfard, F. Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference (1)HNMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives. Chem. Pharm. Bull. (Tokyo),2012, 60(1), 70-78.
155. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR,2000, 18(1), 65-68.
156. Dalvit, C.; Fogliatto, G.; Stewart, A.; Veronesi, M.; Stockman, B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR,2001, 21(4), 349-359.
157. Diaz, M. D.; Palomino-Schatzlein, M.; Corzana, F.; Andreu, C.; Carbajo, R. J.; del Olmo, M.; Canales-Mayordomo, A.; Pineda-Lucena, A.; Asensio, G.; Jimenez-Barbero, J. Antimicrobial peptides and their superior fluorinated analogues: structure-activity relationships as revealed by NMR spectroscopy and MD calculations. ChemBioChem, 2010, 11(17), 2424-2432.
158. Jahnke, W.; Floersheim, P.; Ostermeier, C.; Zhang, X. L.; Hemmig, R.; Hurth, K.; Uzunov, D. P. NMR reporter screening for the detection of high-affinity ligands. Angew. Chem. Int. Ed., 2002, 41(18), 3420-3423.
159. Dalvit, C.; Fagerness, P. E.; Hadden, D. T.; Sarver, R. W.; Stockman, B. J. Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability. J. Am. Chem. Soc., 2003, 125(25), 7696-7703.
160. Vulpetti, A.; Hommel, U.; Landrum, G.; Lewis, R.; Dalvit, C. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. J. Am. Chem. Soc., 2009, 131(36), 12949-12959.
161. Dalvit, C.; Ardini, E.; Fogliatto, G. P.; Mongelli, N.; Veronesi, M. Reliable high-throughput functional screening with 3-FABS. Drug Discov. Today,2004, 9(14), 595-602.
162. Papeo, G.; Giordano, P.; Brasca, M. G.; Buzzo, F.; Caronni, D.; Ciprandi, F.; Mongelli, N.; Veronesi, M.; Vulpetti, A.; Dalvit, C. Polyfluorinated amino acids for sensitive 19F NMR-based screening and kinetic measurements. J. Am. Chem. Soc., 2007, 129(17), 5665-5672.
163. Jahnke, W. Spin labels as a tool to identify and characterize protein-ligand interactions by NMR spectroscopy. ChemBioChem, 2002, 3(2-3), 167-173.
164. Saio, T.; Ogura, K.; Shimizu, K.; Yokochi, M.; Burke, T. R., Jr.; Inagaki, F. An NMR strategy for fragment-based ligand screening utilizing a paramagnetic lanthanide probe. J. Biomol. NMR,2011, 51(3), 395-408.
165. Dai, Y.; Hartandi, K.; Ji, Z.; Ahmed, A. A.; Albert, D. H.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Harris, C. M.; Hickman, D.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Martin, R. L.; Olson, A. M.; Osterling, D. J.; Pease, L. J.; Soni, N. B.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Reuter, D. R.; Davidsen, S. K.; Michaelides, M. R. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2- fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J. Med. Chem., 2007, 50(7), 1584-1597.
166. Linifanib. Drugs R D,2010, 10(2), 111-122.
167. Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Ahmed, A. A.; Albert, D. H.; Arnold, L.; Arries, S. S.; Barlozzari, T.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Wishart, N.; Davidsen, S. K.; Michaelides, M. R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem., 2005, 48(19), 6066-6083.
168. Blackie, J. A.; Bloomer, J. C.; Brown, M. J.; Cheng, H. Y.; Hammond, B.; Hickey, D. M.; Ife, R. J.; Leach, C. A.; Lewis, V. A.; Macphee, C. H.; Milliner, K. J.; Moores, K. E.; Pinto, I. L.; Smith, S. A.; Stansfield, I. G.; Stanway, S. J.; Taylor, M. A.; Theobald, C. J. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg. Med. Chem. Lett., 2003, 13(6), 1067-1070.
169. Boyd, H. F.; Flynn, S. T.; Hickey, D. M.; Ife, R. J.; Jones, M.; Leach, C. A.; Macphee, C. H.; Milliner, K. J.; Rawlings, D. A.; Slingsby, B. P.; Smith, S. A.; Stansfield, I. G.; Tew, D. G.; Theobald, C. J. 2-(Alkylthio)pyrimidin-4- ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2. Bioorg. Med. Chem. Lett., 2000, 10(4), 395-398.
170. Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem., 2008, 51(21), 6902-6915.
171. Petros, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W. Discovery of a potent inhibitor of the antiapoptotic protein BclxL from NMR and parallel synthesis. J. Med. Chem., 2006, 49(2), 656-663.
172. Liebeschuetz, J. W.; Jones, S. D.; Morgan, P. J.; Murray, C. W.; Rimmer, A. D.; Roscoe, J. M.; Waszkowycz, B.; Welsh, P. M.; Wylie, W. A.; Young, S. C.; Martin, H.; Mahler, J.; Brady, L.; Wilkinson, K. PRO-SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J. Med. Chem., 2002, 45(6), 1221-1232.
173. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K. M.; Collins, I.; Davies, N. G.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem., 2008, 51(2), 196-218.
174. Rowlands, M. G.; Newbatt, Y. M.; Prodromou, C.; Pearl, L. H.; Workman, P.; Aherne, W. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem., 2004, 327(2), 176-183.
175. Murray, C. W.; Carr, M. G.; Callaghan, O.; Chessari, G.; Congreve, M.; Cowan, S.; Coyle, J. E.; Downham, R.; Figueroa, E.; Frederickson, M.; Graham, B.; McMenamin, R.; O'Brien, M. A.; Patel, S.; Phillips, T. R.; Williams, G.; Woodhead, A. J.; Woolford, A. J. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J. Med. Chem., 2010, 53(16), 5942-5955.
176. Woodhead, A. J.; Angove, H.; Carr, M. G.; Chessari, G.; Congreve, M.; Coyle, J. E.; Cosme, J.; Graham, B.; Day, P. J.; Downham, R.; Fazal, L.; Feltell, R.; Figueroa, E.; Frederickson, M.; Lewis, J.; McMenamin, R.; Murray, C. W.; O'Brien, M. A.; Parra, L.; Patel, S.; Phillips, T.; Rees, D. C.; Rich, S.; Smith, D. M.; Trewartha, G.; Vinkovic, M.; Williams, B.; Woolford, A. J. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl) -1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem., 2010, 53(16), 5956-5969.
177. Misra, R. N.; Xiao, H. Y.; Kim, K. S.; Lu, S.; Han, W. C.; Barbosa, S. A.; Hunt, J. T.; Rawlins, D. B.; Shan, W.; Ahmed, S. Z.; Qian, L.; Chen, B. C.; Zhao, R.; Bednarz, M. S.; Kellar, K. A.; Mulheron, J. G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.; Ranadive, S. A.; Sack, J. S.; Tokarski, J. S.; Pavletich, N. P.; Lee, F. Y.; Webster, K. R.; Kimball, S. D. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem., 2004, 47(7), 1719-1728.
178. Kim, K. S.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T.; Xiao, H. Y.; Lu, S.; Qian, L.; Han, W. C.; Shan, W.; Mitt, T.; Cai, Z. W.; Poss, M. A.; Zhu, H.; Sack, J. S.; Tokarski, J. S.; Chang, C. Y.; Pavletich, N.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Bursuker, I.; Kellar, K. A.; Roongta, U.; Batorsky, R.; Mulheron, J. G.; Bol, D.; Fairchild, C. R.; Lee, F. Y.; Webster, K. R. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem., 2002, 45(18), 3905-3927.